The case pertains to alleged irregularities in reimbursement claims submitted between 2022 and 2024 under a cashless treatment scheme for railway employees. Unlike chemotherapy, which kills both cancer cells and some healthy cells, ZI-MA4-1 uses specially modified Natural Killer (NK) immune cells to find and destroy cancer cells carrying a protein called MAGE-A4, while causing less harm to healthy tissues. This means the immune cells come from healthy donors and are prepared and stored in advance, instead of being made separately for each patient. Researchers believe this could help patients start treatment faster, lower costs and make advanced cancer therapies available to more people. Although the treatment is still in the early stages of testing and may take years before it becomes widely available, the first successful use of this therapy is an important step forward in cancer treatment, according to an NDTV report.